Showing papers by "Charles University in Prague published in 2012"
TL;DR: In this article, a search for the Standard Model Higgs boson in proton-proton collisions with the ATLAS detector at the LHC is presented, which has a significance of 5.9 standard deviations, corresponding to a background fluctuation probability of 1.7×10−9.
9,282 citations
TL;DR: In this paper, results from searches for the standard model Higgs boson in proton-proton collisions at 7 and 8 TeV in the CMS experiment at the LHC, using data samples corresponding to integrated luminosities of up to 5.8 standard deviations.
8,857 citations
Daniel J. Klionsky1, Fábio Camargo Abdalla2, Hagai Abeliovich3, Robert T. Abraham4 +1284 more•Institutions (463)
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Abstract: In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues to be confusion regarding acceptable methods to measure autophagy, especially in multicellular eukaryotes. A key point that needs to be emphasized is that there is a difference between measurements that monitor the numbers or volume of autophagic elements (e.g., autophagosomes or autolysosomes) at any stage of the autophagic process vs. those that measure flux through the autophagy pathway (i.e., the complete process); thus, a block in macroautophagy that results in autophagosome accumulation needs to be differentiated from stimuli that result in increased autophagic activity, defined as increased autophagy induction coupled with increased delivery to, and degradation within, lysosomes (in most higher eukaryotes and some protists such as Dictyostelium) or the vacuole (in plants and fungi). In other words, it is especially important that investigators new to the field understand that the appearance of more autophagosomes does not necessarily equate with more autophagy. In fact, in many cases, autophagosomes accumulate because of a block in trafficking to lysosomes without a concomitant change in autophagosome biogenesis, whereas an increase in autolysosomes may reflect a reduction in degradative activity. Here, we present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes. These guidelines are not meant to be a formulaic set of rules, because the appropriate assays depend in part on the question being asked and the system being used. In addition, we emphasize that no individual assay is guaranteed to be the most appropriate one in every situation, and we strongly recommend the use of multiple assays to monitor autophagy. In these guidelines, we consider these various methods of assessing autophagy and what information can, or cannot, be obtained from them. Finally, by discussing the merits and limits of particular autophagy assays, we hope to encourage technical innovation in the field.
4,316 citations
TL;DR: The Daya Bay Reactor Neutrino Experiment has measured a nonzero value for the neutrino mixing angle θ(13) with a significance of 5.2 standard deviations.
Abstract: The Daya Bay Reactor Neutrino Experiment has measured a nonzero value for the neutrino mixing angle θ13 with a significance of 5.2 standard deviations. Antineutrinos from six 2.9 GW_(th) reactors were detected in six antineutrino detectors deployed in two near (flux-weighted baseline 470 m and 576 m) and one far (1648 m) underground experimental halls. With a 43 000 ton–GW_(th)–day live-time exposure in 55 days, 10 416 (80 376) electron-antineutrino candidates were detected at the far hall (near halls). The ratio of the observed to expected number of antineutrinos at the far hall is R=0.940± 0.011(stat.)±0.004(syst.). A rate-only analysis finds sin^22θ_(13)=0.092±0.016(stat.)±0.005(syst.) in a three-neutrino framework.
2,163 citations
TL;DR: This consensus document advises on the measurement procedures in general and provides arguments for the use of 80% of the direct carotid-femoral distance as the most accurate distance estimate.
Abstract: Stiffness of elastic arteries like the aorta predicts cardiovascular risk. By directly reflecting arterial stiffness, having the best predictive value for cardiovascular outcome and the ease of its measurement, carotid-femoral pulse wave velocity is now considered the gold standard for arterial stiffness assessment in daily practice. Many different measurement procedures have been proposed. Therefore, standardization of its measurement is urgently needed, particularly regarding the distance measurement. This consensus document advises on the measurement procedures in general and provides arguments for the use of 80% of the direct carotid-femoral distance as the most accurate distance estimate. It also advises the use of 10 m/s as new cut-off value for carotid-femoral pulse wave velocity.
1,471 citations
University of Saskatchewan1, Dalhousie University2, University of Rhode Island3, Sewanee: The University of the South4, Natural History Museum5, New York State Department of Health6, University of British Columbia7, Kaiserslautern University of Technology8, Charles University in Prague9, University of Guelph10, Le Moyne College11, Georgia College & State University12, University of Colorado Boulder13, University of Geneva14, Edinburgh Napier University15, University of Arkansas16, Saint Petersburg State University17
TL;DR: This revision of the classification of eukaryotes retains an emphasis on the protists and incorporates changes since 2005 that have resolved nodes and branches in phylogenetic trees.
Abstract: This revision of the classification of eukaryotes, which updates that of Adl et al. [J. Eukaryot. Microbiol. 52 (2005) 399], retains an emphasis on the protists and incorporates changes since 2005 that have resolved nodes and branches in phylogenetic trees. Whereas the previous revision was successful in re-introducing name stability to the classification, this revision provides a classification for lineages that were then still unresolved. The supergroups have withstood phylogenetic hypothesis testing with some modifications, but despite some progress, problematic nodes at the base of the eukaryotic tree still remain to be statistically resolved. Looking forward, subsequent transformations to our understanding of the diversity of life will be from the discovery of novel lineages in previously under-sampled areas and from environmental genomic information.
1,414 citations
Spanish National Research Council1, University of Cambridge2, Complutense University of Madrid3, Max Planck Society4, Leibniz Institute for Astrophysics Potsdam5, University of La Laguna6, University of Zaragoza7, University of Vienna8, Masaryk University9, University of Sydney10, Centre national de la recherche scientifique11, Ruhr University Bochum12, Autonomous University of Madrid13, Australian Astronomical Observatory14, Paris Diderot University15, University of Copenhagen16, University of Missouri–Kansas City17, Tianjin Normal University18, Institut d'Astrophysique de Paris19, Charles University in Prague20, Academy of Sciences of the Czech Republic21, Macquarie University22, Instituto Superior Técnico23, University of Porto24, Heidelberg University25, University of Granada26, Kapteyn Astronomical Institute27, University of Edinburgh28
TL;DR: The Calar Alto Legacy Integral Field Area (CALIFA) survey as discussed by the authors was designed to provide a first step in this direction by obtaining spatially resolved spectroscopic information of a diameter selected sample of similar to 600 galaxies in the Local Universe.
Abstract: The final product of galaxy evolution through cosmic time is the population of galaxies in the local universe. These galaxies are also those that can be studied in most detail, thus providing a stringent benchmark for our understanding of galaxy evolution. Through the huge success of spectroscopic single-fiber, statistical surveys of the Local Universe in the last decade, it has become clear, however, that an authoritative observational description of galaxies will involve measuring their spatially resolved properties over their full optical extent for a statistically significant sample. We present here the Calar Alto Legacy Integral Field Area (CALIFA) survey, which has been designed to provide a first step in this direction. We summarize the survey goals and design, including sample selection and observational strategy. We also showcase the data taken during the first observing runs (June/July 2010) and outline the reduction pipeline, quality control schemes and general characteristics of the reduced data. This survey is obtaining spatially resolved spectroscopic information of a diameter selected sample of similar to 600 galaxies in the Local Universe (0.005 < z < 0.03). CALIFA has been designed to allow the building of two-dimensional maps of the following quantities: (a) stellar populations: ages and metallicities; (b) ionized gas: distribution, excitation mechanism and chemical abundances; and (c) kinematic properties: both from stellar and ionized gas components. CALIFA uses the PPAK integral field unit (IFU), with a hexagonal field-of-view of similar to 1.3 square', with a 100% covering factor by adopting a three-pointing dithering scheme. The optical wavelength range is covered from 3700 to 7000 angstrom, using two overlapping setups (V500 and V1200), with different resolutions: R similar to 850 and R similar to 1650, respectively. CALIFA is a legacy survey, intended for the community. The reduced data will be released, once the quality has been guaranteed. The analyzed data fulfill the expectations of the original observing proposal, on the basis of a set of quality checks and exploratory analysis: (i) the final datacubes reach a 3 sigma limiting surface brightness depth of similar to 23.0 mag/arcsec(2) for the V500 grating data (similar to 22.8 mag/arcsec(2) for V1200); (ii) about similar to 70% of the covered field-of-view is above this 3 sigma limit; (iii) the data have a blue-to-red relative flux calibration within a few percent in most of the wavelength range; (iv) the absolute flux calibration is accurate within similar to 8% with respect to SDSS; (v) the measured spectral resolution is similar to 85 km s(-1) for V1200 (similar to 150 km s(-1) for V500); (vi) the estimated accuracy of the wavelength calibration is similar to 5 km s(-1) for the V1200 data (similar to 10 km s(-1) for the V500 data); (vii) the aperture matched CALIFA and SDSS spectra are qualitatively and quantitatively similar. Finally, we show that we are able to carry out all measurements indicated above, recovering the properties of the stellar populations, the ionized gas and the kinematics of both components. The associated maps illustrate the spatial variation of these parameters across the field, reemphasizing the redshift dependence of single aperture spectroscopic measurements. We conclude from this first look at the data that CALIFA will be an important resource for archaeological studies of galaxies in the Local Universe.
1,143 citations
TL;DR: It is shown that there is no universal measure of impact and the pattern observed depends on the ecological measure examined, and some species traits, especially life form, stature and pollination syndrome, may provide a means to predict impact, regardless of the particular habitat and geographical region invaded.
Abstract: With the growing body of literature assessing the impact of invasive alien plants on resident species and ecosystems, a comprehensive assessment of the relationship between invasive species traits and environmental settings of invasion on the characteristics of impacts is needed. Based on 287 publications with 1551 individual cases that addressed the impact of 167 invasive plant species belonging to 49 families, we present the first global overview of frequencies of significant and non-significant ecological impacts and their directions on 15 outcomes related to the responses of resident populations, species, communities and ecosystems. Species and community outcomes tend to decline following invasions, especially those for plants, but the abundance and richness of the soil biota, as well as concentrations of soil nutrients and water, more often increase than decrease following invasion. Data mining tools revealed that invasive plants exert consistent significant impacts on some outcomes (survival of resident biota, activity of resident animals, resident community productivity, mineral and nutrient content in plant tissues, and fire frequency and intensity), whereas for outcomes at the community level, such as species richness, diversity and soil resources, the significance of impacts is determined by interactions between species traits and the biome invaded. The latter outcomes are most likely to be impacted by annual grasses, and by wind pollinated trees invading mediterranean or tropical biomes. One of the clearest signals in this analysis is that invasive plants are far more likely to cause significant impacts on resident plant and animal richness on islands rather than mainland. This study shows that there is no universal measure of impact and the pattern observed depends on the ecological measure examined. Although impact is strongly context dependent, some species traits, especially life form, stature and pollination syndrome, may provide a means to predict impact, regardless of the particular habitat and geographical region invaded.
1,067 citations
TL;DR: Alemtuzumab's consistent safety profile and benefit in terms of reductions of relapse support its use for patients with previously untreated relapsing-remitting multiple sclerosis; however, benefit interms of disability endpoints noted in previous trials was not observed here.
1,020 citations
TL;DR: This 2 year, rater-masked, randomised controlled phase 3 trial enrolled adults aged 18-55 years with relapsing-remitting multiple sclerosis and at least one relapse on interferon beta or glatiramer and found alemtuzumab could be used to reduce relapse rates and sustained accumulation of disability.
1,020 citations
University of Texas MD Anderson Cancer Center1, Medical University of Lublin2, Medical University of Łódź3, Wrocław Medical University4, Masaryk University5, National Taiwan University6, University of Toronto7, Charles University in Prague8, Chang Gung University9, Autonomous University of Barcelona10, University of Nantes11, Royal North Shore Hospital12
TL;DR: In older patients with AML, decitabine improved response rates compared with standard therapies without major differences in safety, and an unplanned survival analysis showed a benefit for decit abine, which was not observed at the time of the primary analysis.
Abstract: Purpose This multicenter, randomized, open-label, phase III trial compared the efficacy and safety of decitabine with treatment choice (TC) in older patients with newly diagnosed acute myeloid leukemia (AML) and poor- or intermediate-risk cytogenetics. Patients and Methods Patients (N = 485) age ≥ 65 years were randomly assigned 1:1 to receive decitabine 20 mg/m2 per day as a 1-hour intravenous infusion for five consecutive days every 4 weeks or TC (supportive care or cytarabine 20 mg/m2 per day as a subcutaneous injection for 10 consecutive days every 4 weeks). The primary end point was overall survival (OS); the secondary end point was the complete remission (CR) rate plus the CR rate without platelet recovery (CRp). Adverse events (AEs) were recorded. Results The primary analysis with 396 deaths (81.6%) showed a nonsignificant increase in median OS with decitabine (7.7 months; 95% CI, 6.2 to 9.2) versus TC (5.0 months; 95% CI, 4.3 to 6.3; P = .108; hazard ratio [HR], 0.85; 95% CI, 0.69 to 1.04). An unp...
University of Crete1, National and Kapodistrian University of Athens2, University of Paris3, Leiden University Medical Center4, Radboud University Nijmegen5, University of Barcelona6, Charité7, University of Padua8, RWTH Aachen University9, Cliniques Universitaires Saint-Luc10, Stanford University11, University College London12, University Medical Center Groningen13, Imperial College London14, Great Ormond Street Hospital15, University of Genoa16, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico17, Complutense University of Madrid18, University of Düsseldorf19, Charles University in Prague20, University of Porto21, Karolinska University Hospital22, Hannover Medical School23, University of Birmingham24
TL;DR: Recommendations for the management of lupus nephritis were developed using an evidence-based approach followed by expert consensus and there is no evidence to suggest that management of LN should differ in children versus adults.
Abstract: Objectives To develop recommendations for the management of adult and paediatric lupus nephritis (LN).
TL;DR: The concept of sustainable development from 1980 to the present has evolved into definitions of the three pillars of sustainability (social, economic and environmental). The recent economic and financial crisis has helped to newly define economic sustainability as discussed by the authors.
Ruhr University Bochum1, Leiden University2, National Autonomous University of Mexico3, University of Córdoba (Spain)4, Rikshospitalet–Radiumhospitalet5, University of Amsterdam6, University of Paris7, University of Leeds8, Eötvös Loránd University9, Hamad Medical Corporation10, University of Toronto11, Case Western Reserve University12, University of Helsinki13, University of Alberta14, Charles University in Prague15, Erciyes University16, VU University Amsterdam17
TL;DR: This first update of the ASAS/EULAR recommendations on the management of ankylosing spondylitis is based on the original paper, a systematic review of existing recommendations and the literature since 2005 and the discussion and agreement among 21 international experts, 2 patients and 2 physiotherapists in a meeting in February 2010.
University of Cambridge1, University of Kiel2, University of East Anglia3, University of Copenhagen4, University of Manchester5, Karolinska Institutet6, Maastricht University7, Wellcome Trust Sanger Institute8, Trinity College, Dublin9, University of Paris10, University of Birmingham11, Charles University in Prague12, University College London13, University of Parma14, University of Jena15, Lund University16, University of Glasgow17, Imperial College London18, GlaxoSmithKline19, Linköping University20, Ruhr University Bochum21, University of Erlangen-Nuremberg22, Medical University of Vienna23
TL;DR: This study confirms that the pathogenesis of ANCA-associated vasculitis has a genetic component, shows genetic distinctions between granulomatosis with polyang iitis and microscopic polyangiitis that are associated with ANCA specificity, and suggests that the response against the autoantigen proteinase 3 is a central pathogenic feature ofproteinase 3 ANCA -associated vasulitis.
Abstract: BACKGROUND Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a severe condition encompassing two major syndromes: granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis) and microscopic polyangiitis. Its cause is unknown, and there is debate about whether it is a single disease entity and what role ANCA plays in its pathogenesis. We investigated its genetic basis. METHODS A genomewide association study was performed in a discovery cohort of 1233 U. K. patients with ANCA-associated vasculitis and 5884 controls and was replicated in 1454 Northern European case patients and 1666 controls. Quality control, population stratification, and statistical analyses were performed according to standard criteria. RESULTS We found both major-histocompatibility-complex (MHC) and non-MHC associations with ANCA-associated vasculitis and also that granulomatosis with polyangiitis and microscopic polyangiitis were genetically distinct. The strongest genetic associations were with the antigenic specificity of ANCA, not with the clinical syndrome. Anti-proteinase 3 ANCA was associated with HLA-DP and the genes encoding alpha(1)-antitrypsin (SERPINA1) and proteinase 3 (PRTN3) (P = 6.2x10(-89), P = 5.6x10(-12), and P = 2.6x10(-7), respectively). Anti-myeloperoxidase ANCA was associated with HLA-DQ (P = 2.1x10(-8)). CONCLUSIONS This study confirms that the pathogenesis of ANCA-associated vasculitis has a genetic component, shows genetic distinctions between granulomatosis with polyangiitis and microscopic polyangiitis that are associated with ANCA specificity, and suggests that the response against the autoantigen proteinase 3 is a central pathogenic feature of proteinase 3 ANCA-associated vasculitis. These data provide preliminary support for the concept that proteinase 3 ANCA-associated vasculitis and myeloperoxidase ANCA-associated vasculitis are distinct autoimmune syndromes. (Funded by the British Heart Foundation and others.)
29 Mar 2012
TL;DR: In this article, the authors reported results from searches for the standard model Higgs boson in proton-proton collisions at square root(s) = 7 TeV in five decay modes: gamma pair, b-quark pair, tau lepton pair, W pair, and Z pair.
Abstract: Combined results are reported from searches for the standard model Higgs boson in proton-proton collisions at sqrt(s)=7 TeV in five Higgs boson decay modes: gamma pair, b-quark pair, tau lepton pair, W pair, and Z pair. The explored Higgs boson mass range is 110-600 GeV. The analysed data correspond to an integrated luminosity of 4.6-4.8 inverse femtobarns. The expected excluded mass range in the absence of the standard model Higgs boson is 118-543 GeV at 95% CL. The observed results exclude the standard model Higgs boson in the mass range 127-600 GeV at 95% CL, and in the mass range 129-525 GeV at 99% CL. An excess of events above the expected standard model background is observed at the low end of the explored mass range making the observed limits weaker than expected in the absence of a signal. The largest excess, with a local significance of 3.1 sigma, is observed for a Higgs boson mass hypothesis of 124 GeV. The global significance of observing an excess with a local significance greater than 3.1 sigma anywhere in the search range 110-600 (110-145) GeV is estimated to be 1.5 sigma (2.1 sigma). More data are required to ascertain the origin of this excess.
TL;DR: The EuroFlow studies resulted in validated and flexible 8-color antibody panels for multidimensional identification and characterization of normal and aberrant cells, optimally suited for immunophenotypic screening and classification of hematological malignancies.
Abstract: Most consensus leukemia & lymphoma antibody panels consist of lists of markers based on expert opinions, but they have not been validated. Here we present the validated EuroFlow 8-color antibody panels for immunophenotyping of hematological malignancies. The single-tube screening panels and multi-tube classification panels fit into the EuroFlow diagnostic algorithm with entries defined by clinical and laboratory parameters. The panels were constructed in 2–7 sequential design–evaluation–redesign rounds, using novel Infinicyt software tools for multivariate data analysis. Two groups of markers are combined in each 8-color tube: (i) backbone markers to identify distinct cell populations in a sample, and (ii) markers for characterization of specific cell populations. In multi-tube panels, the backbone markers were optimally placed at the same fluorochrome position in every tube, to provide identical multidimensional localization of the target cell population(s). The characterization markers were positioned according to the diagnostic utility of the combined markers. Each proposed antibody combination was tested against reference databases of normal and malignant cells from healthy subjects and WHO-based disease entities, respectively. The EuroFlow studies resulted in validated and flexible 8-color antibody panels for multidimensional identification and characterization of normal and aberrant cells, optimally suited for immunophenotypic screening and classification of hematological malignancies.
Cincinnati Children's Hospital Medical Center1, Istituto Giannina Gaslini2, Hoffmann-La Roche3, University of Toronto4, Great Ormond Street Hospital5, Katholieke Universiteit Leuven6, Universidade Federal do Rio Grande do Sul7, National Health Service8, National Autonomous University of Mexico9, Charles University in Prague10, Autonomous University of Madrid11, Ghent University12, Utrecht University13, University of Padua14
TL;DR: Tocilizumab was efficacious in severe, persistent systemic JIA and adverse events were common and included infection, neutropenia, and increased aminotransferase levels.
Abstract: Background Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA; treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. Methods We randomly assigned 112 children, 2 to 17 years of age, with active systemic JIA (duration of ≥6 months and inadequate responses to nonsteroidal antiinflammatory drugs and glucocorticoids) to the anti–interleukin-6 receptor antibody tocilizumab (at a dose of 8 mg per kilogram of body weight if the weight was ≥30 kg or 12 mg per kilogram if the weight was <30 kg) or placebo given intravenously every 2 weeks during the 12-week, double-blind phase. Patients meeting the predefined criteria for nonresponse were offered open-label tocilizumab. All patients could enter an open-label extension. Results At week 12, the primary end point (an absence of fever and an improvement of 30% or more on at least three of the six variables in the American College of Rheumatology [ACR] core set for JIA, with no more than one variable worsening...
Duke University1, Uppsala University2, University of Kentucky3, University of Alberta4, Katholieke Universiteit Leuven5, Auckland City Hospital6, Flinders University7, Merck & Co.8, University of Tennessee Health Science Center9, University of Perugia10, University of Freiburg11, University of Barcelona12, Ufuk University13, Henry Ford Health System14, Peking Union Medical College15, Leiden University16, Cleveland Clinic17, Pierre-and-Marie-Curie University18, University of São Paulo19, Kumamoto University20, University of Basel21, University of Chile22, University of Sheffield23, University of Ferrara24, Thomas Jefferson University25, Charles University in Prague26
TL;DR: In patients with acute coronary syndromes, the addition of vorapaxar to standard therapy did not significantly reduce the primary composite end point but significantly increased the risk of major bleeding, including intracranial hemorrhage.
Abstract: In patients with acute coronary syndromes, the addition of vorapaxar to standard therapy did not significantly reduce the primary composite end point but significantly increased the risk of major bleeding, including intracranial hemorrhage. (Funded by Merck; TRACER ClinicalTrials.gov number, NCT00527943.).
University of Turin1, Masaryk University2, University of Münster3, Sapienza University of Rome4, Monash University5, Medical University of Vienna6, Medical University of Warsaw7, University of Tübingen8, Casa Sollievo della Sofferenza9, University of Bologna10, Medical University of Białystok11, Ankara University12, Charles University in Prague13, Dresden University of Technology14, University of Ulm15, Celgene16, National and Kapodistrian University of Athens17
TL;DR: MPR-R significantly prolonged progression-free survival in patients with newly diagnosed multiple myeloma who were ineligible for transplantation, with the greatest benefit observed in patients 65 to 75 years of age.
Abstract: The median follow-up period was 30 months. The median progression-free survival was significantly longer with MPR-R (31 months) than with MPR (14 months; hazard ratio, 0.49; P<0.001) or MP (13 months; hazard ratio, 0.40; P <0.001). Response rates were superior with MPR-R and MPR (77% and 68%, respectively, vs. 50% with MP; P<0.001 and P = 0.002, respectively, for the comparison with MP). The progression-free survival benefit associated with MPR-R was noted in patients 65 to 75 years of age but not in those older than 75 years of age (P = 0.001 for treatment-by-age interaction). After induction therapy, a landmark analysis showed a 66% reduction in the rate of progression with MPR-R (hazard ratio for the comparison with MPR, 0.34; P<0.001) that was age-independent. During induction therapy, the most frequent adverse events were hematologic; grade 4 neutropenia was reported in 35%, 32%, and 8% of the patients in the MPR-R, MPR, and MP groups, respectively. The 3-year rate of second primary tumors was 7% with MPR-R, 7% with MPR, and 3% with MP. Conclusions MPR-R significantly prolonged progression-free survival in patients with newly di agnosed multiple myeloma who were ineligible for transplantation, with the great est benefit observed in patients 65 to 75 years of age. (Funded by Celgene; MM-015 ClinicalTrials.gov number, NCT00405756.)
TL;DR: Polyploidy can be an important factor in species invasion success through a combination of 'pre-adaptation', whereby polyploid lineages are predisposed to conditions in the new range and, therefore, have higher survival rates and fitness in the earliest establishment phase.
Centre national de la recherche scientifique1, Butterfly Conservation2, Catalan Ornithological Institute3, British Trust for Ornithology4, Finnish Environment Institute5, Lund University6, Charles University in Prague7, Helmholtz Centre for Environmental Research - UFZ8, Statistics Netherlands9, Radboud University Nijmegen10, Wageningen University and Research Centre11
TL;DR: In this article, the authors quantified the yearly change in community composition in response to climate change for 9,490 bird and 2,130 butterfly communities distributed across Europe and found that changes in community compositions are rapid but different between birds and butterflies and equivalent to a 37 and 114 km northward shift in bird and butterfly communities, respectively.
Abstract: Climate changes have profound effects on the distribution of numerous plant and animal species(1-3). However, whether and how different taxonomic groups are able to track climate changes at large spatial scales is still unclear. Here, we measure and compare the climatic debt accumulated by bird and butterfly communities at a European scale over two decades (1990-2008). We quantified the yearly change in community composition in response to climate change for 9,490 bird and 2,130 butterfly communities distributed across Europe(4). We show that changes in community composition are rapid but different between birds and butterflies and equivalent to a 37 and 114 km northward shift in bird and butterfly communities, respectively. We further found that, during the same period, the northward shift in temperature in Europe was even faster, so that the climatic debts of birds and butterflies correspond to a 212 and 135 km lag behind climate. Our results indicate both that birds and butterflies do not keep up with temperature increase and the accumulation of different climatic debts for these groups at national and continental scales.
TL;DR: Treatment with ulipristal acetate for 13 weeks effectively controlled excessive bleeding due to uterine fibroids and reduced the size of the fibroid.
Abstract: At 13 weeks, uterine bleeding was controlled in 91% of the women receiving 5 mg of ulipristal acetate, 92% of those receiving 10 mg of ulipristal acetate, and 19% of those receiving placebo (P<0.001 for the comparison of each dose of ulipristal acetate with placebo). The rates of amenorrhea were 73%, 82%, and 6%, respectively, with amenorrhea occurring within 10 days in the majority of patients receiving ulipristal acetate. The median changes in total fibroid volume were −21%, −12%, and +3% (P = 0.002 for the comparison of 5 mg of ulipristal acetate with placebo, and P = 0.006 for the comparison of 10 mg of ulipristal acetate with placebo). Ulipristal acetate induced benign histologic endometrial changes that had resolved by 6 months after the end of therapy. Serious adverse events occurred in one patient during treatment with 10 mg of ulipristal acetate (uterine hemorrhage) and in one patient during receipt of placebo (fibroid protruding through the cervix). Headache and breast tenderness were the most common adverse events associated with ulipristal acetate but did not occur significantly more frequently than with placebo. Conclusions Treatment with ulipristal acetate for 13 weeks effectively controlled excessive bleeding due to uterine fibroids and reduced the size of the fibroids. (Funded by PregLem; ClinicalTrials.gov number, NCT00755755.)
TL;DR: A combined search for the Standard Model Higgs boson with the ATLAS experiment at the LHC using datasets corresponding to integrated luminosities from 1.04 fb(-1) to 4.9 fb(1) of pp collisions is described in this paper.
TL;DR: The 6 years of extensive collaborative experiments and the analysis of hundreds of cell samples of patients and healthy controls have provided for the first time laboratory protocols and software tools for fully standardized 8-color flow cytometric immunophenotyping of normal and malignant leukocytes in bone marrow and blood; this has yielded highly comparable data sets, which can be integrated in a single database.
Abstract: The EU-supported EuroFlow Consortium aimed at innovation and standardization of immunophenotyping for diagnosis and classification of hematological malignancies by introducing 8-color flow cytometry with fully standardized laboratory procedures and antibody panels in order to achieve maximally comparable results among different laboratories. This required the selection of optimal combinations of compatible fluorochromes and the design and evaluation of adequate standard operating procedures (SOPs) for instrument setup, fluorescence compensation and sample preparation. Additionally, we developed software tools for the evaluation of individual antibody reagents and antibody panels. Each section describes what has been evaluated experimentally versus adopted based on existing data and experience. Multicentric evaluation demonstrated high levels of reproducibility based on strict implementation of the EuroFlow SOPs and antibody panels. Overall, the 6 years of extensive collaborative experiments and the analysis of hundreds of cell samples of patients and healthy controls in the EuroFlow centers have provided for the first time laboratory protocols and software tools for fully standardized 8-color flow cytometric immunophenotyping of normal and malignant leukocytes in bone marrow and blood; this has yielded highly comparable data sets, which can be integrated in a single database.
TL;DR: In this article, the performance of muon reconstruction, identification, and triggering in CMS has been studied using 40 inverse picobarns of data collected in pp collisions at the LHC in 2010.
Abstract: The performance of muon reconstruction, identification, and triggering in CMS has been studied using 40 inverse picobarns of data collected in pp collisions at sqrt(s) = 7 TeV at the LHC in 2010. A few benchmark sets of selection criteria covering a wide range of physics analysis needs have been examined. For all considered selections, the efficiency to reconstruct and identify a muon with a transverse momentum pT larger than a few GeV is above 95% over the whole region of pseudorapidity covered by the CMS muon system, abs(eta)<2.4, while the probability to misidentify a hadron as a muon is well below 1%. The efficiency to trigger on single muons with pT above a few GeV is higher than 90% over the full eta range, and typically substantially better. The overall momentum scale is measured to a precision of 0.2% with muons from Z decays. The transverse momentum resolution varies from 1% to 6% depending on pseudorapidity for muons with pT below 100 GeV and, using cosmic rays, it is shown to be better than 10% in the central region up to pT = 1 TeV. Observed distributions of all quantities are well reproduced by the Monte Carlo simulation.
J. L. Abelleira Fernandez1, J. L. Abelleira Fernandez2, C. Adolphsen3, A. Akay4 +195 more•Institutions (54)
TL;DR: The Large Hadron Electron Collider (LHeC) as discussed by the authors was designed to achieve an integrated luminosity of O(100 ),fb$^{-1}, which is the cleanest high resolution microscope of mankind.
Abstract: This document provides a brief overview of the recently published report on the design of the Large Hadron Electron Collider (LHeC), which comprises its physics programme, accelerator physics, technology and main detector concepts. The LHeC exploits and develops challenging, though principally existing, accelerator and detector technologies. This summary is complemented by brief illustrations of some of the highlights of the physics programme, which relies on a vastly extended kinematic range, luminosity and unprecedented precision in deep inelastic scattering. Illustrations are provided regarding high precision QCD, new physics (Higgs, SUSY) and electron-ion physics. The LHeC is designed to run synchronously with the LHC in the twenties and to achieve an integrated luminosity of O(100)\,fb$^{-1}$. It will become the cleanest high resolution microscope of mankind and will substantially extend as well as complement the investigation of the physics of the TeV energy scale, which has been enabled by the LHC.
Book•
01 Aug 2012TL;DR: In this paper, the authors introduce the concept of space-time related to Schwarzchild and Taub-NUT space-times, and provide solutions for uniformly accelerating particles in the plane and pp-wave domain.
Abstract: Preface 1. Introduction 2. Basic tools and concepts 3. Minkowski space-time 4. de Sitter space-time 5. Anti-de Sitter space-time 6. Friedmann-Lemaitre-Robertson-Walker space-times 7. Electrovacuum and related background space-times 8. Schwarzchild space-time 9. Space-times related to Schwarzchild 10. Static axially symmetric space-times 11. Rotating black holes 12. Taub-NUT space-time 13. Stationary, axially symmetric space-times 14. Accelerating black holes 15. Further solutions for uniformly accelerating particles 16. Plebanski-Demianski solutions 17. Plane and pp-waves 18. Kundt solutions 19. Robinson-Trautman solutions 20. Impulsive waves 21. Colliding plane waves 22. A final miscellany Appendix A. 2-spaces of constant curvature Appendix B. 3-spaces of constant curvature References Index.
University of Cologne1, Charles University in Prague2, Heidelberg University3, Masaryk University4, University of Tübingen5, University of Ulm6, Charité7, Ludwig Maximilian University of Munich8, University of Würzburg9, University of Hamburg10, University of Duisburg-Essen11, Leipzig University12, University of Münster13, University of Salzburg14, University Hospital Regensburg15, Saarland University16
TL;DR: Treatment with six cycles of BEACOPP(escalated) followed by PET-guided radiotherapy was more effective in terms of freedom from treatment failure and less toxic than eight cycles of the same chemotherapy regimen, and should be the treatment of choice for advanced stage Hodgkin's lymphoma.
French Institute of Health and Medical Research1, University of Montpellier2, University of Erlangen-Nuremberg3, Ghent University4, National and Kapodistrian University of Athens5, Imperial College London6, University of Genoa7, Oslo University Hospital8, Nova Southeastern University9, University of Helsinki10, University of Aberdeen11, Medical University of Warsaw12, University of Manitoba13, Boston Children's Hospital14, Karolinska Institutet15, Pierre-and-Marie-Curie University16, Charité17, Odense University Hospital18, Creighton University19, Federal University of Bahia20, Vilnius University21, University of Amsterdam22, Erasmus University Rotterdam23, Hacettepe University24, Medical University of Łódź25, Monash University26, Teikyo University27, Charles University in Prague28, Silesian University29, Loughborough University30, University of Edinburgh31, University of Coimbra32, Medical University of Vienna33
TL;DR: The Practical guide to skin prick tests in allergy to aeroallergens 2012; 67: 18–24 is cited.
Abstract: To cite this article: Bousquet J, Heinzerling L, Bachert C, Papadopoulos NG, Bousquet PJ, Burney PG, Canonica GW, Carlsen KH, Cox L, Haahtela T, Lodrup Carlsen KC, Price D, Samolinski B, Simons FER, Wickman M, Annesi-Maesano I, Baena-Cagnani CE, Bergmann KC, Bindslev-Jensen C, Casale TB, Chiriac A, Cruz AA, Dubakiene R, Durham SR, Fokkens WJ, Gerth-van-Wijk R, Kalayci O, Kowalski ML, Mari A, Mullol J, Nazamova-Baranova L, O'Hehir RE, Ohta K, Panzner P, Passalacqua G, Ring J, Rogala B, Romano A, Ryan D, Schmid-Grendelmeier P, Todo-Bom A, Valenta R, Woehrl S, Yusuf OM, Zuberbier T, Demoly P. Practical guide to skin prick tests in allergy to aeroallergens. Allergy 2011; DOI: 10.1111/j.1398-9995.2011.02728.x ABSTRACT: This pocket guide is the result of a consensus reached between members of the Global Allergy and Asthma European Network (GA(2) LEN) and Allergic Rhinitis and its Impact on Asthma (ARIA). The aim of the current pocket guide is to offer a comprehensive set of recommendations on the use of skin prick tests in allergic rhinitis-conjunctivitis and asthma in daily practice. This pocket guide is meant to give simple answers to the most frequent questions raised by practitioners in Europe, including 'practicing allergists', general practitioners and any other physicians with special interest in the management of allergic diseases. It is not a long or detailed scientific review of the topic. However, the recommendations in this pocket guide were compiled following an in-depth review of existing guidelines and publications, including the 1993 European Academy of Allergy and Clinical Immunology position paper, the 2001 ARIA document and the ARIA update 2008 (prepared in collaboration with GA(2) LEN). The recommendations cover skin test methodology and interpretation, allergen extracts to be used, as well as indications in a variety of settings including paediatrics and developing countries.